First Time Loading...

Inhibrx Inc
NASDAQ:INBX

Watchlist Manager
Inhibrx Inc Logo
Inhibrx Inc
NASDAQ:INBX
Watchlist
Price: 34.61 USD
Updated: Apr 18, 2024

Intrinsic Value

INBX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. [ Read More ]

The intrinsic value of one INBX stock under the Base Case scenario is 25.95 USD. Compared to the current market price of 34.61 USD, Inhibrx Inc is Overvalued by 25%.

Key Points:
INBX Intrinsic Value
Base Case
25.95 USD
Overvaluation 25%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Inhibrx Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling INBX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Inhibrx Inc

Provide an overview of the primary business activities
of Inhibrx Inc.

What unique competitive advantages
does Inhibrx Inc hold over its rivals?

What risks and challenges
does Inhibrx Inc face in the near future?

Has there been any significant insider trading activity
in Inhibrx Inc recently?

What significant events have occurred
in Inhibrx Inc over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Inhibrx Inc.

Provide P/S
for Inhibrx Inc.

Provide P/E
for Inhibrx Inc.

Provide P/OCF
for Inhibrx Inc.

Provide P/FCFE
for Inhibrx Inc.

Provide P/B
for Inhibrx Inc.

Provide EV/S
for Inhibrx Inc.

Provide EV/GP
for Inhibrx Inc.

Provide EV/EBITDA
for Inhibrx Inc.

Provide EV/EBIT
for Inhibrx Inc.

Provide EV/OCF
for Inhibrx Inc.

Provide EV/FCFF
for Inhibrx Inc.

Provide EV/IC
for Inhibrx Inc.

Show me price targets
for Inhibrx Inc made by professional analysts.

What are the Revenue projections
for Inhibrx Inc?

How accurate were the past Revenue estimates
for Inhibrx Inc?

What are the Net Income projections
for Inhibrx Inc?

How accurate were the past Net Income estimates
for Inhibrx Inc?

What are the EPS projections
for Inhibrx Inc?

How accurate were the past EPS estimates
for Inhibrx Inc?

What are the EBIT projections
for Inhibrx Inc?

How accurate were the past EBIT estimates
for Inhibrx Inc?

Compare the revenue forecasts
for Inhibrx Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Inhibrx Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Inhibrx Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Inhibrx Inc compared to its peers.

Compare the P/E ratios
of Inhibrx Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Inhibrx Inc with its peers.

Analyze the financial leverage
of Inhibrx Inc compared to its main competitors.

Show all profitability ratios
for Inhibrx Inc.

Provide ROE
for Inhibrx Inc.

Provide ROA
for Inhibrx Inc.

Provide ROIC
for Inhibrx Inc.

Provide ROCE
for Inhibrx Inc.

Provide Gross Margin
for Inhibrx Inc.

Provide Operating Margin
for Inhibrx Inc.

Provide Net Margin
for Inhibrx Inc.

Provide FCF Margin
for Inhibrx Inc.

Show all solvency ratios
for Inhibrx Inc.

Provide D/E Ratio
for Inhibrx Inc.

Provide D/A Ratio
for Inhibrx Inc.

Provide Interest Coverage Ratio
for Inhibrx Inc.

Provide Altman Z-Score Ratio
for Inhibrx Inc.

Provide Quick Ratio
for Inhibrx Inc.

Provide Current Ratio
for Inhibrx Inc.

Provide Cash Ratio
for Inhibrx Inc.

What is the historical Revenue growth
over the last 5 years for Inhibrx Inc?

What is the historical Net Income growth
over the last 5 years for Inhibrx Inc?

What is the current Free Cash Flow
of Inhibrx Inc?

Financials

Balance Sheet Decomposition
Inhibrx Inc

Current Assets 295.4m
Cash & Short-Term Investments 277.9m
Receivables 778k
Other Current Assets 16.7m
Non-Current Assets 12.5m
PP&E 9.4m
Other Non-Current Assets 3.2m
Current Liabilities 56.3m
Accounts Payable 11m
Accrued Liabilities 45.4m
Non-Current Liabilities 208.1m
Long-Term Debt 207m
Other Non-Current Liabilities 1.1m
Efficiency

Earnings Waterfall
Inhibrx Inc

Revenue
1.8m USD
Operating Expenses
-221m USD
Operating Income
-219.2m USD
Other Expenses
-22.1m USD
Net Income
-241.4m USD

Free Cash Flow Analysis
Inhibrx Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

INBX Profitability Score
Profitability Due Diligence

Inhibrx Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

29/100
Profitability
Score

Inhibrx Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

INBX Solvency Score
Solvency Due Diligence

Inhibrx Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
High D/E
31/100
Solvency
Score

Inhibrx Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

INBX Price Targets Summary
Inhibrx Inc

Wall Street analysts forecast INBX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for INBX is 36.21 USD with a low forecast of 35.35 USD and a high forecast of 37.8 USD.

Lowest
Price Target
35.35 USD
2% Upside
Average
Price Target
36.21 USD
5% Upside
Highest
Price Target
37.8 USD
9% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

INBX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

INBX Price
Inhibrx Inc

1M 1M
-1%
6M 6M
+102%
1Y 1Y
+70%
3Y 3Y
+87%
5Y 5Y
+68%
10Y 10Y
+68%
Annual Price Range
34.61
52w Low
14.5
52w High
39.56
Price Metrics
Average Annual Return 14.54%
Standard Deviation of Annual Returns 52.89%
Max Drawdown -83%
Shares Statistics
Market Capitalization 1.6B USD
Shares Outstanding 47 392 400
Percentage of Shares Shorted 6.95%

INBX Return Decomposition
Main factors of price return

What is price return decomposition?

INBX News

Last Important Events
Inhibrx Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Inhibrx Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Inhibrx Inc Logo
Inhibrx Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.6B USD

Dividend Yield

0%

Description

Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The company is headquartered in La Jolla, California and currently employs 106 full-time employees. The company went IPO on 2020-08-19. The Company’s single domain antibody (sdAb) platform provides a small, simple, modular target binding domain that can be combined in to meet the needs of each biological target. Its products pipeline includes: INBRX-101 is a recombinant alpha-1 antitrypsin (AAT) protein that is comprised of two human AAT, molecules covalently linked to the fragment crystallizable (Fc) region of human immunoglobulin G4; INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate targeting death-receptor 5 (DR5) that designed with its sdAb platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis, and INBRX-105 is a precisely engineered multi-specific sdAb-based therapeutic candidate that is designed to agonize 4-1BB selectively in the presence of PD-L1.

Contact

CALIFORNIA
La Jolla
11025 N. Torrey Pines Road, Suite 200
+18587954220.0
https://inhibrx.com/

IPO

2020-08-19

Employees

106

Officers

Founder, Chairman, President & CEO
Mr. Mark Paul Lappe
Founder & Chief Scientific Officer
Dr. Brendan P. Eckelman Ph.D.
Executive VP & CFO
Ms. Kelly Devine Deck B.S., CPA, M.S.
Founder
Mr. Quinn L. Deveraux
Executive VP & Chief Technical Operations Officer
Dr. Ashraf Amanullah
VP, Corporate Secretary & General Counsel
Ms. Leah Pollema J.D.
Show More
Vice President of Marketing & Commercial Planning
Dr. Charbel Helaihel Pharm.D.
Executive VP & Chief Clinical Operations Officer
Mr. Jeffrey J. Jensen
Executive VP and Chief Commercial & Business Development Officer
Mr. David Matly M.B.A.
Executive Vice President of Translational Sciences
Dr. Carlos Bais Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one INBX stock?

The intrinsic value of one INBX stock under the Base Case scenario is 25.95 USD.

Is INBX stock undervalued or overvalued?

Compared to the current market price of 34.61 USD, Inhibrx Inc is Overvalued by 25%.